In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment ...

When multiple myeloma comes back after standard treatments like lenalidomide and daratumumab, patients often need new options ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T cell engagers, along with potent new CELMoD drugs, all offering more targeted and effective ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Patients with newly diagnosed multiple myeloma (NDMM) treated at a specialized clinic have improved outcomes, with median overall survival (OS) of 152 months, according to a research letter published ...

When multiple myeloma returns after a period of remission, treatment plans often need to be adjusted because the cancer may have become resistant to previous medications. Doctors determine the most ...

Immunotherapy is a type of cancer treatment that uses the power of a person’s immune system to fight their cancer. Instead of directly attacking cancer cells like chemotherapy or radiation, ...

Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Treatment costs for multiple myeloma are higher than those for many other types of cancer. One reason for this is that multiple myeloma is a chronic condition that may require treatment for years. If ...

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National ...